Mayo Clinic in Arizona

Phase	Trial	Trial Status	Site Status [desc]	Drug	NCT#
1	Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors	Suspended	Closed	Navitoclax + Sorafenib	NCT02143401
3	A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib (intrigue)	Active, not recruiting	Active	QINLOCK Ripretinib DCC-2618 SUTENT Sunitinib	NCT03673501
3	(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors	Recruiting	Active	Bezuclastinib plus Sunitinib	NCT05208047